Millie Das, MD
Medical Oncology · Palo Alto, CANPI 1225182322
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $110,234 of the $151,682 with a category attached, or 72.7%. It is spread thinly across 26 manufacturers, the largest accounting for just 18.4%. 2025 is the largest year on record at $47,811, 8.9 times the $5,361 reported in 2019.
Across 190 payments — averaging $798.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$28K
- Jazz Pharmaceuticals Inc.$21K
- Novocure Inc.$18K
- E.r. Squibb & Sons, L.L.C.$15K
- Johnson & Johnson$11K
- Sanofi$10K
- plus $48K from 20 others
Across 35 payments — averaging $12,862 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$310K
- Novartis$49K
- AbbVie$44K
- Genentech, Inc.$28K
- United Therapeutics Corporation$16K
- Bristol Myers Squibb$3K
- plus $1K from 1 others
What the payments were for
- Consulting fees$110,23473%
- Speaking & faculty fees$29,42019%
- Travel & lodging$4,9153%
- Food & beverage$7,0615%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $27,967 |
| Jazz Pharmaceuticals Inc. | 21 | $21,159 |
| Novocure Inc. | 24 | $18,089 |
| E.r. Squibb & Sons, L.L.C. | 11 | $15,180 |
| Johnson & Johnson | 11 | $10,982 |
| Sanofi | 5 | $10,306 |
| AbbVie | 4 | $6,086 |
| Eli Lilly | 2 | $5,200 |
| Gilead | 8 | $4,228 |
| Partner Therapeutics, Inc. | 12 | $4,073 |
| Astrazeneca UK Limited | 1 | $3,768 |
| Boehringer Ingelheim | 1 | $3,553 |
| Regeneron Healthcare Solutions, Inc. | 7 | $3,507 |
| EMD Serono, Inc. | 2 | $3,377 |
| Regeneron | 2 | $2,996 |
| Genentech USA, Inc. | 8 | $2,716 |
| Catalyst Pharmaceuticals, Inc. | 3 | $2,413 |
| Beigene, Ltd. | 1 | $1,452 |
| Daiichi Sankyo Inc. | 17 | $1,424 |
| Janssen Scientific Affairs, LLC | 1 | $1,350 |
| Bristol Myers Squibb | 1 | $1,288 |
| Genentech, Inc. | 8 | $446 |
| Zap Surgical Systems, Inc. | 1 | $54 |
| Amgen | 1 | $39 |
| ADC Therapeutics America, Inc. | 1 | $18 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$151,682 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Palo Alto
- Ann LowePalo Alto$923K
- Milana DolezalPalo Alto$135K
- Curtis ChongPalo Alto$99K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Marin XavierSan Diego$919K
- Munveer Bhangoola Jolla$804K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.